SCHEMBL20209713

SCHEMBL20209713

CCCCC(=O)c1cn(-c2c(F)ccc(Cl)c2F)nn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTR7 P34969 1/20 0.36
P2RX7 Q99572 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
KLKB1 P03952 1/20 0.35
NOTUM Q6P988 6/20 0.35
GABRA2 P47869 3/20 0.35
GABRB2 P47870 3/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CA12 O43570 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18933508 0.88 KMT2A (0.42) KMT2ACYP2C19KDM4EALDH1A1MAPT
SCHEMBL15933197 0.81 KMT2A (0.44) KMT2AKDM4EALDH1A1MAPTKLKB1
SCHEMBL14692497 0.80 NOTUM (0.52) KMT2AKDM4EALDH1A1MAPTKLKB1
SCHEMBL14706103 0.78 KMT2A (0.42) KMT2AKDM4EALDH1A1MAPTKLKB1
SCHEMBL18933509 0.69 P2RX7 (0.45) KMT2AP2RX7ALDH1A1NOTUMRAB9A
SCHEMBL18945325 0.68 RXRA (0.48) KLKB1NOTUM
SCHEMBL19412818 0.65 NOTUM (0.56) KMT2ANOTUMNPC1RAB9ASMN1; SMN2
SCHEMBL18944628 0.65 PTGS2 (0.47) KMT2AALDH1A1MAPTGABRA2GABRB2
SCHEMBL15933233 0.64 NOTUM (0.39) KMT2AHPGDKDM4EALDH1A1MAPT
SCHEMBL17570893 0.64 EGLN1 (0.38) MAPTKLKB1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10208068-B2 Macrocycles as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2019-02-19 US disclosed
US-20180148461-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148461-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F12 KMT2A 1182/4885CYP1A2 1559/4885CYP3A4 1148/4885
US-10208068-B2 Macrocycles as factor XIa inhibitors TFPI, TFPI2, F12 KMT2A 1029/4885CYP1A2 1285/4885CYP3A4 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.